aTyr Pharma, Inc.
Histidyl-tRNA synthetase-Fc conjugates

Last updated:

Abstract:

The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.

Status:
Grant
Type:

Utility

Filling date:

7 Apr 2020

Issue date:

27 Jul 2021